Effect [qlco]
Drug Therapy [topp]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
High density lipoprotein [aapp, bacs, lipd]
enriched [food]
Serum [bdsu]
Rheumatoid Arthritis [dsyn]
Objective [inpr]
Patients [podg]
Rheumatoid Arthritis [dsyn]
Increased [qnco]
Risk [qlco]
coronary heart disease [dsyn]
arthritis therapies [topp]
MODIFY [ftcn]
Risk [qlco]
Mechanisms [ftcn]
cholesterol efflux [celf]
Capacity [qnco]
High density lipoprotein [aapp, bacs, lipd]
Associated [qlco]
Reduced [qlco]
Coronary heart disease risk [inpr]
Non [ftcn]
Rheumatoid Arthritis [dsyn]
Population [qnco]
Inflammation [patf]
function [phsf]
High density lipoprotein [aapp, bacs, lipd]
Aim [idcn]
Study [mnob]
To [qlco]
Evaluate [ftcn]
Reduced [qlco]
Inflammation [patf]
treatment [ftcn]
Methotrexate [orch, phsu]
adalimumab [aapp, imft, phsu]
tocilizumab [aapp, imft, phsu]
Increase [ftcn]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
High density lipoprotein [aapp, bacs, lipd]
Patients [podg]
Rheumatoid Arthritis [dsyn]
Methods [inpr]
Longitudinal [spco]
Multicenter Study [resa]
Repository [mnob]
Treatment Efficacy [qlco]
toxicity [qlco]
Rheumatoid Arthritis [dsyn]
Database [inpr]
Repository [mnob]
Provided [acty]
Clinical information [clna]
Serum sample [bdsu]
Patients [podg]
Rheumatoid Arthritis [dsyn]
months [tmco]
Start [tmco]
treatment [ftcn]
New [tmco]
Drug [phsu]
Methotrexate [orch, phsu]
N NOS [aapp, imft]
adalimumab [aapp, imft, phsu]
N NOS [aapp, imft]
tocilizumab [aapp, imft, phsu]
N NOS [aapp, imft]
Disease [dsyn]
activity [dora]
Measured [qlco]
Using [ftcn]
Disease [dsyn]
activity [dora]
Score [qnco]
Joints [bsoj]
Using [ftcn]
Erythrocyte Sedimentation Rate [lbpr]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
Measured [qlco]
Paired [qlco]
Serum sample [bdsu]
Using [ftcn]
THP [gngm]
Macrophages [cell]
Total Cholesterol [lbpr]
Cellular [cell]
Measured [qlco]
Fluorimetry [lbpr]
Assay [lbpr]
Result [ftcn]
Disease [dsyn]
activity [dora]
Score [qnco]
Joints [bsoj]
Using [ftcn]
Erythrocyte Sedimentation Rate [lbpr]
Decreased [qnco]
Treatments [topp]
P NOS [aapp, imft]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
Not [ftcn]
Changed [ftcn]
months [tmco]
new therapy [idcn]
Rheumatoid Arthritis [dsyn]
Units [qnco]
baseline [bodm]
Units [qnco]
months [tmco]
P NOS [aapp, imft]
Change [ftcn]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
Associated [qlco]
Change [ftcn]
In joint [spco]
Disease [dsyn]
activity [dora]
Score [qnco]
Using [ftcn]
Erythrocyte Sedimentation Rate [lbpr]
P NOS [aapp, imft]
Post [tmco]
Analysis [lbpr]
Patients [podg]
Impaired [ftcn]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
baseline [bodm]
treatment [ftcn]
tocilizumab [aapp, imft, phsu]
Result [ftcn]
Improvement [cnce]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
Units [qnco]
baseline [bodm]
Units [qnco]
months [tmco]
P NOS [aapp, imft]
Not [ftcn]
Observed [ftcn]
Methotrexate [orch, phsu]
adalimumab [aapp, imft, phsu]
Conclusion [idcn]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
High Density Lipoprotein Cholesterol [bacs, lipd]
Not [ftcn]
Change [ftcn]
months [tmco]
new therapy [idcn]
Rheumatoid Arthritis [dsyn]
Patients [podg]
Impaired [ftcn]
baseline [bodm]
cholesterol efflux [celf]
Capacity [qnco]
Receive [qlco]
tocilizumab [aapp, imft, phsu]
Change [ftcn]
Disease [dsyn]
activity [dora]
Associated [qlco]
Change [ftcn]
Reticular [spco]
cholesterol efflux [celf]
Capacity [qnco]
